36 results on '"Nygaard, Gro Owren"'
Search Results
2. Norsk helsevesen bør tilby stamcellebehandling mot multippel sklerose.
3. T cell responses to SARS-CoV-2 vaccination differ by disease-modifying therapy for multiple sclerosis
4. Magnetic resonance imaging perfusion is associated with disease severity and activity in multiple sclerosis
5. T cell responses to SARS-CoV-2 vaccination in people with multiple sclerosis differ between disease-modifying therapies
6. Risk of fingolimod rebound after switching to cladribine or rituximab in multiple sclerosis
7. Immunogenicity and Safety of a Third SARS-CoV-2 Vaccine Dose in Patients With Multiple Sclerosis and Weak Immune Response After COVID-19 Vaccination
8. A Comparison of Brain Age Estimation And Brain Parenchymal Fraction as Imaging Markers in Multiple Sclerosis
9. Humoral immunity to SARS-CoV-2 mRNA vaccination in multiple sclerosis: the relevance of time since last rituximab infusion and first experience from sporadic revaccinations
10. Efficacy and safety of a third SARS-CoV-2 vaccination in multiple sclerosis vaccine non-responders
11. Functional connectivity in multiple sclerosis modelled as connectome stability: A 5-year follow-up study
12. Humoral immunity to SARS-CoV-2 mRNA vaccination in multiple sclerosis: the relevance of time since last rituximab infusion and first experience from sporadic revaccinations
13. sj-docx-2-msj-10.1177_13524585211030212 – Supplemental material for Functional connectivity in multiple sclerosis modelled as connectome stability: A 5-year follow-up study
14. sj-docx-1-msj-10.1177_13524585211030212 – Supplemental material for Functional connectivity in multiple sclerosis modelled as connectome stability: A 5-year follow-up study
15. Functional connectivity in multiple sclerosis modelled as connectome stability: A 5-year follow-up study.
16. Behandling som begrenser multippel sklerose
17. Rettelse: Behandling som begrenser multippel sklerose
18. Five years functional connectivity reorganization without clinical or cognitive decline in MS
19. Disease-modifying therapy for multiple sclerosis.
20. Symptoms of fatigue and depression is reflected in altered default mode network connectivity in multiple sclerosis
21. Symptoms of fatigue and depression is reflected in altered default mode network connectivity in multiple sclerosis
22. Cognition, disease activity and MRI changes in early multiple sclerosis
23. Hjerneslag i sykehus
24. A longitudinal study of disability, cognition and gray matter atrophy in early multiple sclerosis patients according to evidence of disease activity
25. Environmental exposures and the risk of multiple sclerosis investigated in a Norwegian case-control study
26. S.M. Moen og medarbeidere svarer
27. MR-undersøkelser ved multippel sklerose
28. The Expression of Vesicular Glutamate Transporters Defines Two Classes of Excitatory Synapse
29. Norwegian Study of Oral Cladribine and Rituximab in Multiple Sclerosis (NOR-MS) (NOR-MS)
30. Humoral immunity to SARS-CoV-2 mRNA vaccination in multiple sclerosis: the relevance of time since last rituximab infusion and first experience from sporadic revaccinations.
31. Functional connectivity in multiple sclerosis modelled as connectome stability: A 5-year follow-up study.
32. Correction: Disease-modifying therapy for multiple sclerosis.
33. Disease-modifying therapy for multiple sclerosis.
34. [In-hospital stroke].
35. [MRI in multiple sclerosis].
36. Environmental exposures and the risk of multiple sclerosis investigated in a Norwegian case-control study.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.